Fremanezumab
A Norwegian syringe of fremanezumab | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Calcitonin gene-related peptide (CGRP) α, β |
| Clinical data | |
| Trade names | Ajovy |
| Other names | TEV-48125, fremanezumab-vfrm |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618053 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Calcitonin gene-related peptide antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 55–66% |
| Metabolism | Proteolysis |
| Elimination half-life | 30–31 days (estimated) |
| Excretion | Kidney |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6470H9952N1716O2016S46 |
| Molar mass | 145507.54 g·mol−1 |
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by subcutaneous injection (injection under the skin).
The most common side effect is pain and redness at the site of injection. Other side effects include allergic reactions. It is in the calcitonin gene-related peptide antagonist class of medications.
It was approved for medical use in the United States in 2018, the European Union in 2019, the United Kingdom in 2020, and Argentina by September 2021.